Molecule to Market: Inside the outsourcing space

Biopharma Global Supply veteran

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Robert Bottome, a global supply veteran.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Robert, covering:

• Stretching yourself by tapping into the collective wisdom of others
• The challenge of pairing internal production capacity with the need for agile, rapid early phase R&D
• The decision to leave Genentech to do a 'do over' and do things better at a growing biotech company
• Why strategic partnerships are easy on a PowerPoint but hard to realize in practice fully

Now retired, Robert is an accomplished and results-driven supply chain and operations leader with extensive experience overseeing and driving global supply chain operations and operational efficiency for organizations in the biotechnology and pharmaceutical industries (including Genentech and BioMarin).

He has experience managing end-to-end supply chain functions, including global logistics, production planning, trade compliance, and product launches. He has a background in transforming cross-functional teams and implementing strategic initiatives optimizing production schedules, reducing cycle times, and improving supply resilience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Meet the healthcare futurist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Imran Kausar, Founder of DeepHealth Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Imran, covering:

• His unusual blend of experience led to a road into big pharma...
• Switching the security of Big Pharma to join an exciting, scrappy, start-up biotech... before an exit to Roche
• Being part of the gene therapies evolution with an innovative biotech that later became Novartis Gene Therapies
• His views on the thorny issue of CGT products' price (and value)
• Opting to start his own business aimed at supporting the future of healthcare

Imran Kausar is a visionary healthcare and life sciences leader, blending medical expertise with strategic foresight. A medical doctor by training, Imran specialized in anesthesia and critical care before transitioning to the pharmaceutical industry. Having launched five rare disease medicines and spearheaded innovative work in gene therapies like Zolgensma and Luxturna across Europe, Imran has earned his reputation as a trailblazer in the industry.

As the founder of DeepHealth Consulting, Imran leads the flagship program DeepHealth Futures, which equips life sciences teams to navigate the transformative forces of AI, longevity science, and precision medicine.With nearly two decades of experience in medicine, medical affairs, and general management, Imran’s career spans the cutting edge of rare diseases, antisense oligonucleotides, and healthcare transformation. 

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

The dynamic duo driving global growth

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with James Lovett, CEO and Mike Cohen, Executive Chairman at Myonex.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with James and Mike, covering:

• How a family-owned pharmacy became a major global clinical trial supplies business... two generations later
• Mike's decision to bring in a CEO and the challenge of letting go... before seeing the data points of success
• James' decision to take on the baton and fuel organic and inorganic growth through client-centricity
• The decision not to take investment and instead 'run our own play' using some of PE's tried and tested playbook
• Why this industry will always grow due to unmet medical needs and breakthroughs in science

Michael’s passion and commitment have been a driving force in making Myonex, a global leader in clinical trial supply. Under his leadership, Myonex has expanded its service offerings and strengthened manufacturer and sourcing relationships, opened new locations and expanded the employee base. Today Michael focuses on strategic growth opportunities. Before Myonex, he served in executive positions in the publishing, advertising, financial and utility industries. He holds a BS in Statistics from the University of Pittsburgh and an MBA from the university’s Katz Graduate School of Business.

James is driven to help clients deliver medical advances, to develop team members, and to lead Myonex to continued success. Before joining Myonex in 2017 as Chief Operating Officer, James was SVP of Covance, where he led three business units, was General Counsel and served on the Executive Committee. He was named Myonex CEO in 2019. He also serves on the Board of Directors of Food Chain ID and the Board of Trustees of the Wistar Institute. James has played leadership roles in the Association of Clinical Research Organizations and the National Association for Biomedical Research. He is a graduate of Northwestern University and Harvard Law School.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Biopharma Insights: Live from J.P. Morgan

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dean McAlister, Executive Vice President at Inizio Biotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dean, covering:

• The evolving dynamics within the life sciences sector and how they are shaping outsourcing strategies
• Key insights and trends from J.P. Morgan week, including challenges and opportunities for CROs and CDMOs
• The Impact of cautious optimism on Business Development teams and commercial strategy in the current market Climate
• Why 2025 may be a year of incremental growth and how contract service providers can position themselves for success amidst swirling market headwinds
• The importance of strategic customer engagement and brand positioning for smaller, specialized players to gain an edge over global CDMO giants

Dean brings a wealth of experience from his leadership role at Inizio Biotech, where he focuses on driving growth, innovation, and operational excellence. Prior to joining Inizio, he held executive leadership roles at AstraZeneca in US Commercial Sales and Market Access, leading teams of up to 1,100 people and overseeing high-impact strategies in a highly competitive environment.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

 

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

The CEO making a global impact

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter DeYoung, CEO at Piramal Global Pharma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• Why did Peter fall in love with the pharma sector? Why did he decide to leave McKinsey and jump into PE?
• The value of living and working in different places, and why you should jump at the chance if you ever get the opportunity to do it
• Avoiding the 'peanut butter strategy' and divesting non-core activities to prioritize truly
• Piramal's secret sauce of differentiating 'magnets' that attract new clients, and the importance of genuinely listening to customers
• The elements that make India such a superpower drive the belief that 'this is India's century'
• Supply chain security and resiliency, 'friend-shoring' and onshoring, and preparing for uncertainty and change

Peter DeYoung is Piramal Global Pharma's CEO, comprising Piramal Pharma Solutions and Piramal Critical Care business units. In his current role, Peter is responsible for steering strategy and driving profitable growth of these businesses. Before this, he spearheaded several leadership mandates at the Piramal Group, including the CEO of Piramal Critical Care and the President of Life Sciences.

Previously, Peter worked in various investing and consulting roles in healthcare in the USA, Europe and India. After graduating from Princeton, he joined McKinsey & Company in New York, where he worked on several projects for pharmaceutical and medical device companies. Later, he joined the Blackstone Group’s Private Equity Division in Mumbai, where he was part of the deal team for several significant transactions across a broad spectrum of industry sectors in India.

Peter holds a Master’s Degree in Business Administration from Stanford University (Arjay Miller Scholar), California, USA and a Bachelor of Science Degree in Engineering from Princeton University, New Jersey, USA (summa cum laude).

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

 

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

2024 reflections and 2025 outlook in pharma services

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ian Tzeng, a Managing Director and Partner in L.E.K. Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering:

• Reflections on 2024's market dynamics, shifting sponsor behavior, big pharma woes, biotech rebound and segment-specific impact
• The outlook for 2025 across discovery, development, clinical trials, and manufacturing
• The uptick Ian expects and where companies should be focusing efforts

Ian Tzeng, a Managing Director and Partner in L.E.K.’s Boston office, joined the company in 1998 with experience in growth strategy, regulated markets, innovation, pricing, and mergers and acquisitions. He focuses on healthcare and life sciences, including pharmaceuticals, vaccines and medical devices. 

 

He leads L.E.K.’s Pharmaceutical Contract Services practice, including CROs, CDMOs, supply chain and distribution, commercial, medical, and market access services. Other areas of deep experience include rare diseases, biodefense, biosimilars and generics, and consumer-directed healthcare. 

Additionally, Ian has extensive consulting and board experience with nonprofit organizations in education, arts, LGBT advocacy and public service. He received a Bachelor of Arts degree, magna cum laude, in chemistry from Harvard College and is a George F. Baker Scholar, Master of Business Administration with high distinction from Harvard Business School.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

 

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

 

From questions to answers: Celebrating 200 episodes

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Raman Sehgal, Founder & Global President at ramarketing & Host of Molecule to Market.

For this milestone episode, your host is Molecule to Market’s first guest from back in 2020, JoyL Silva, Customer Engagement Lead for the US Primary Care portfolio at Pfizer, who discusses the pharmaceutical and biotechnology supply chain with Raman Sehgal covering:

• Raman reflects on the podcast’s evolution, from its inception during COVID-19 to becoming a globally recognized platform
• They discuss key trends in the pharma outsourcing sector and the impact of guests who have contributed to the podcast’s success
• Raman shares highlights from his career, including the growth of his companies, ramarketing and Lead Candidate, and his private equity ventures
• Insights into balancing work and family life, with advice on being present and managing priorities
• A desert island question where Raman chooses which podcast guests he’d bring along, plus behind-the-scenes stories of challenges and humorous incidents

JoyL Silva is the Customer Engagement Lead for Pfizer’s US Primary Care portfolio, overseeing sales and account management across therapeutic areas such as Migraine, Cardiovascular, Anti-virals, and Vaccines. She leads high-performing teams that drive a $20B portfolio through agile methodologies and talent development. With over 20 years at Pfizer, JoyL has excelled in commercial leadership, business transformations, and operational expertise, delivering impactful results across multiple roles, including VP for Hematology and Biosimilars, General Manager of Pfizer CentreOne, and US/Global Commercial Lead for PAXLOVID, where she spearheaded global strategies and partnerships for Pfizer’s COVID-19 antiviral therapeutic.

JoyL frequently speaks at industry forums and contributes her expertise to various publications and professional boards, including the Pharma & Biopharma Outsourcing Association. Her accolades include being named to the Medicine Maker Power List and PharmaVOICE 100 Most Inspiring People in the Life Sciences Industry, as well as receiving awards such as the Scrip Best Partnership Alliance Award and Putnam Media Top 20 Influential Women in Manufacturing. Her career reflects a strong commitment to driving innovation and fostering leadership in the life sciences sector.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

 

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Charles River's lifelong CDMO leader

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kerstin Dolph, Senior Vice President of Manufacturing at Charles River Laboratories.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kerstin, covering:

• The value of having managers and mentors guide you and champion your success
• Navigating transitions from finance to operations and research to biologics manufacturing while becoming a senior leader at CRL
• Tackling the task of integrating testing and manufacturing at CRL globally to cut timelines for clients
• The importance of staying close and connected to the patient so you never lose sight of the impact of the work done in this space
• Stabilizing signs in the biotech market and pivoting to the market's needs in creative ways

Kerstin joined Charles River 2001 in a Finance role for the Company’s Research Models and Services (RMS) business in Germany. She transitioned to the U.S. RMS business in 2009 and was promoted to Senior Finance Director of Global RMS in 2015.

In 2017, Ms Dolph was promoted to Corporate Vice President of North American RMS, responsible for leading the Company’s North American RMS business. This included managing several consolidation and efficiency initiatives and global RMS technology enhancements.

In 2019, Ms Dolph assumed the role of Corporate Vice President of Global Biologics. Subsequently, she assumed responsibility for the Company’s CDMO business and was promoted to senior vice president of biologics solutions in October 2021. Ms. Dolph is currently the Senior Vice President of Manufacturing. She is responsible for driving each business's strategic direction and future growth within the Company’s Manufacturing Solutions segment, including Biologics Testing Solutions, CDMO, and Microbial Solutions.

Ms. Dolph holds a bachelor’s degree from the International Accountancy & Business School in Wuerzburg, Germany and was recognised by the Bavarian Government for outstanding performance.

 

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

The pharma ingredients disruptor

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jack Stine, Chief Executive Officer at Savendor.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jack, covering:

• What he learned about supplier relationship management from exposure to 70 supply chain sourcing teams in 3M
• The shift to sourcing APIs and excipients for generics and med devices under FDA regulations
• How he always wanted to start a business, take the plunge, and fall in love with being a founder
• The actual trend of secondary sourcing... as opposed to immediate switching
• And what is Minnesota nice?!

Since founding Savendor in 2023, Jack Stine has pioneered a new model for pharma sourcing teams to move faster, cut out intermediaries, added clients from 4 continents, and built an industry-leading portfolio of 331 pharmaceutical ingredient manufacturers. Savendor has been accepted into AstraZeneca’s Diverse and Small Business Mentorship Program and BetaMN’s startup accelerator. Jack has presented Savendor at both CPHI Philadelphia and CPHI Milan.

Jack has worked in sourcing for over a decade. His career has brought him to APIs, excipients, industrial products, services, food, and medical device components. He has shared his knowledge by leading the Negotiations Training Team at Boston Scientific and speaking to undergraduates at the University of Minnesota’s Carlson School of Management. Jack has a Supply Chain Management Degree from the University of Minnesota and an MBA from IE Business School. Beyond sourcing and supply chain, Jack volunteers his time at the Ukrainian American Community Center as he is passionate about supporting people affected by the war in Ukraine.

 

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Baking success to IQVIA exit

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tessa Pugh, ex-CEO & Co-Founder at PharmaReview.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tessa, covering:

• How Tessa's bullish attitude led to her becoming a co-founder at PharmaReview
• Being the 'less educated person in the office', and using that to drive the growth of the business
• Opting not to leave after the sale of the business, and becoming the CEO
• Being the star player within a PE portfolio, leading to a quick exit to IQVIA
• Life lessons on having your cake...and eating it!

Tessa Pugh is the former CEO & Co-founder PharmaReview, a Mum and an athlete. She spent 13 years working with Pharma companies and their agencies; she Co-Founded PharmaReview in 2011. Tessa was responsible for ensuring excellent client service, business development for both new and existing clients. She is a Pharma copy review process expert and became an expert in Veeva Vault functionality.

Prior to this, she established a luxury direct-to-consumer cupcake company and worked in client service at some of the world’s leading advertising agencies including Saatchi & Saatchi and DRAFT. She is a very proud Mum to two incredible young women. Tessa has completed several marathons; has competed in triathlons and has won an age group national title in track cycling. She is currently following a life-long dream and training to be a ski instructor.

 

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

 

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.